

FOR IMMEDIATE RELEASE

PluroGen Therapeutics, Inc. to Attend European Wound Management Association (EWMA) Conference 23-25 May in Vienna, AU

Norristown, PA, 14 May, 2012

PluroGen Therapeutics, Inc, an emerging leader in advanced wound care solutions, announced today that it will be attending the European Wound Management Association (EWMA) conference to be held at the Austria Center in Vienna on 23-25 May, 2012. PluroGen will be discussing and demonstrating its PluroGel[®] line of wound care products, recent strategic developments and product pipeline. Neal Koller, President and CEO of PluroGen and Kati Weiss, PluroGen Europe, will be available throughout the conference for one-on-one meetings at the PluroGen Booth #37a, located in the conference center. To set up a meeting during the show with a PluroGen representative please email Europe@plurogen.com.

PluroGen has developed a portfolio of 3 synergistic and complementary patented technologies, including PluroGel[®] technologies, which are sharply focused on the burn and non-healing wounds (including chronic wound) market. PluroGel PSSD[®], one of PluroGen's line of patented Gel-based products is being used in burn and wound centers across Europe. "Our team is very excited about attending the EWMA show. There is no better forum than this to meet the people who really make a difference for patients in wound care" said Neal Koller, President and CEO of PluroGen. "We want to tell our story about how PluroGel[®] technology can help physicians make great strides in their day to day wound care challenges."

About PluroGen Therapeutics, Inc.

PluroGen Therapeutics, Inc. provides technically advanced wound and skin care products. PluroGen's University developed products are simple yet advanced to support complex wounds to benefit patients, with an added advantage for the delicate needs of burn and wound patients in the \$7B worldwide wound care market. PluroGen offers healthcare providers new, unique and cost-effective wound care tools. A key initiative for PluroGen is bringing the unique patented PluroGel[®] product line to doctors, nurses and patients in Europe to provide the best options in wound care to help patients have a better quality of life. PluroGen's headquarters and operations facility is in Norristown, PA USA, with sales and marketing offices in Europe. More information can be found on the company's website: www.plurogen.com.

About European Wound Management Association

The European Wound Management Association (EWMA) was founded in 1991, and the association works to promote the advancement of education and research into native epidemiology, pathology, diagnosis, prevention and management of wounds of all aetiologies. Over 2000 experts, practitioners and company representatives working with wound healing and wound management will be in attendance. Additional information on the conference can be found at <http://www.ewma2012.org>.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties which could cause the company's actual operating results, performance, business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.